Shares of BeyondSpring Inc. slid to $0.78, extending a brutal week that has erased roughly 21% of the stock's value since August 10, after second-quarter results laid bare how little runway the company has left to fund its make-or-break cancer drug trial. BeyondSpring's Cash Is Draining Fast — Is $6.5 Million Enough to Keep Its Cancer Drug Alive?

Shares of BeyondSpring sank to $0.78, deepening a selloff that has wiped out roughly 21% of the stock's value in a single week, after Friday's second-quarter report exposed a stark reality: the company posted a $1.8 million net loss with zero revenue , and held just $6.5 million in cash and short-term investments at June 30 . For a pre-revenue biotech staking everything on one late-stage lung cancer trial, the numbers raise an existential question about whether the money will last.

  • The Cash Won't Cover a 442-Patient Trial. BeyondSpring's planned DUBLIN-4 study is a randomized, double-blind Phase 3 trial enrolling 442 patients with a specific type of advanced lung cancer . A trial of that size typically costs tens of millions of dollars. No financing has been committed — the company says it is only preparing to raise money . At the current quarterly burn rate, the $6.5 million on hand buys roughly three to four quarters of bare-bones operations before the trial even starts. Analysts note that "consistently negative operating cash flow indicates reliance on external funding," and that the ongoing burn "can delay programs, force unfavorable financings, or necessitate asset sales."

  • The Science Looks Promising, but Promise Doesn't Pay Bills. Updated data presented at ASCO 2026 showed a 58% two-year survival rate for patients on BeyondSpring's drug combination , and a prior Phase 3 study published in The Lancet Respiratory Medicine showed the treatment doubled two- and three-year survival rates while slashing a severe side effect from 33% to 5% . This is the company's main pitch for why DUBLIN-4 deserves funding — but investors are clearly weighing science against solvency.

  • A Market Cap Under $35 Million Limits Options. BeyondSpring's market capitalization sits at roughly $34.5 million , and the stock recently hit a 52-week low of $0.73 . A company this small raising the capital needed for a major trial would almost certainly mean issuing a large number of new shares, heavily diluting — or reducing the ownership stake of — existing shareholders. Trading volume on the earnings day surged to 777,000 shares, nearly three times the daily average , signaling active investor flight.

  • New Leadership, Same Old Problem. Min Qiu was installed as CEO in July with a "focused mandate to execute the DUBLIN-4 trial" , but his top priority — advancing "regulatory, operational and financing preparations necessary to initiate DUBLIN-4" — is essentially an admission that the company cannot yet afford to start its most important study. The six-month net loss narrowed slightly to $4.1 million from $4.5 million a year earlier , a modest improvement that does nothing to close a funding gap measured in the tens of millions.